AbolerIS Pharma announces publication in Journal of Clinical Investigation on preclinical and translational data supporting use in Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy syndrome (APECED or APS-1).
Our Approach
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.
IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.
Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.

Our Company



